Palmitoleic Acid-d13
(Synonyms: (9Z)-Hexadecenoic Acid-d13, C16:1(9Z)-d13, C16:1 n-7-d13, cis-Palmitoleic Acid-d13) 目录号 : GC47863
A neuropeptide with diverse biological activities
Cas No.:2692623-92-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Palmitoleic acid-d13 is intended for use as an internal standard for the quantification of palmitoleic acid by GC- or LC-MS. Palmitoleic acid is an ω-7 monounsaturated fatty acid that has been found in macadamia and sea buckthorn oils.1,2 It increases basal and insulin-stimulated glucose uptake and glucose transporter 4 (Glut4) protein levels in 3T3-L1 adipocytes when used at a concentration of 200 µM.3 Ex vivo, palmitoleic acid (300 mg/kg per day) increases glucose uptake and aerobic and anaerobic glycolysis and reduces de novo fatty acid synthesis and activity of the lipogenic enzymes ATP citrate lyase (ACL) and glucose-6-phosphate dehydrogenase (G6PDH) in isolated murine adipocytes. Dietary administration of palmitoleic acid (300 mg/kg) reduces high-fat diet-induced insulin resistance and liver inflammation in mice.4
1.Yang, B., and Kallio, H.P.Fatty acid composition of lipids in sea buckthorn (HippophaË rhamnoids L.) berries of different originsJ. Agric. Food Chem.49(4)1939-1947(2001) 2.Fard, A.M., Turner, A.G., and Willett, G.D.High-resolution electrospray-ionization fourier-transform ion cyclotron resonance and gas chromatography-mass spectrometry of macadamia nut oilAus. J. Chem.56(5)499-508(2003) 3.Bolsoni-Lopes, A., Festuccia, W.T., Chimin, P., et al.Palmitoleic acid (n-7) increases white adipocytes GLUT4 content and glucose uptake in association with AMPK activationLipids Health Dis.13(199)1-10(2014) 4.Souza, C.O., Teixeira, A.A.S., Lima, E.A., et al.Palmitoleic acid (N-7) attenuates the immunometabolic disturbances caused by a high-fat diet independently of PPARɑMediators Inflamm.2014(582197)1-12(2014)
| Cas No. | 2692623-92-8 | SDF | |
| 别名 | (9Z)-Hexadecenoic Acid-d13, C16:1(9Z)-d13, C16:1 n-7-d13, cis-Palmitoleic Acid-d13 | ||
| Canonical SMILES | [2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])/C=C\CCCCCCCC(O)=O[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])/C=C\CCCCCCCC(O)=O | ||
| 分子式 | C16H17D13O2 | 分子量 | 267.5 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: >50 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7383 mL | 18.6916 mL | 37.3832 mL |
| 5 mM | 0.7477 mL | 3.7383 mL | 7.4766 mL |
| 10 mM | 0.3738 mL | 1.8692 mL | 3.7383 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。